AlphaValue/Baader Europe Ups Qiagen EPS Estimates on Operational Performance Beat

12:38 AM EST, 12/16/2025 (MT Newswires) -- AlphaValue/Baader Europe upgraded its EPS forecasts for Qiagen (QIA.F) to incorporate the molecular diagnostics company's "enhanced" profitability amid foreign exchange and tariff pressures. In a Monday note, analysts raised their projected EPS for full-year 2025 and 2026 by 5.33% and 4.33%, respectively, to $2.25 and $2.47. "This improvement is attributed to healthy topline growth, contributions from ongoing efficiency programmes, and the discontinuation of NeuMoDx," the research firm wrote. AlphaValue/Baader Europe rates the stock at add, with a price target of 46.5 euros.